163 related articles for article (PubMed ID: 23224129)
1. [Therapy of stage III retinal angiomatous proliferation. Intravitreal ranibizumab injections].
Maier M; Perz C; Bockmaier J; Feucht N; Lohmann CP
Ophthalmologe; 2013 Dec; 110(12):1171-8. PubMed ID: 23224129
[TBL] [Abstract][Full Text] [Related]
2. One year results of intravitreal ranibizumab monotherapy for retinal angiomatous proliferation: a comparative analysis based on disease stages.
Park YG; Roh YJ
BMC Ophthalmol; 2015 Dec; 15():182. PubMed ID: 26691185
[TBL] [Abstract][Full Text] [Related]
3. Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation.
Cho HJ; Lee TG; Han SY; Kim HS; Kim JH; Han JI; Lew YJ; Kim JW
Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):23-30. PubMed ID: 25825231
[TBL] [Abstract][Full Text] [Related]
4. Visual and morphological outcomes of bevacizumab (Avastin®) versus ranibizumab (Lucentis®) treatment for retinal angiomatous proliferation.
Hufendiek K; Hufendiek K; Panagakis G; Helbig H; Gamulescu MA
Int Ophthalmol; 2012 Jun; 32(3):259-68. PubMed ID: 22527448
[TBL] [Abstract][Full Text] [Related]
5. Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration.
Lai TY; Chan WM; Liu DT; Lam DS
Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1877-80. PubMed ID: 17901972
[TBL] [Abstract][Full Text] [Related]
6. [Retinal angiomatous proliferation with associated pigment epithelium detachment: anti-VEGF therapy].
Lommatzsch A; Heimes B; Gutfleisch M; Spital G; Dietzel M; Pauleikhoff D
Ophthalmologe; 2011 Mar; 108(3):244-51. PubMed ID: 20571805
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal ranibizumab treatment of retinal angiomatous proliferation.
Kramann CA; Schöpfer K; Lorenz K; Zwiener I; Stoffelns BM; Pfeiffer N
Acta Ophthalmol; 2012 Aug; 90(5):487-91. PubMed ID: 20584002
[TBL] [Abstract][Full Text] [Related]
8. Optical coherence tomography-based ranibizumab monotherapy for retinal angiomatous proliferation in Korean patients.
Shin JY; Yu HG
Retina; 2014 Dec; 34(12):2359-66. PubMed ID: 25011025
[TBL] [Abstract][Full Text] [Related]
9. Ranibizumab in retinal angiomatous proliferation (RAP): influence of RAP stage on visual outcome.
Reche-Frutos J; Calvo-Gonzalez C; Pérez-Trigo S; Fernandez-Perez C; Donate-Lopez J; Garcia-Feijoo J
Eur J Ophthalmol; 2011; 21(6):783-8. PubMed ID: 21484755
[TBL] [Abstract][Full Text] [Related]
10. Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme.
Heimes B; Lommatzsch A; Zeimer M; Gutfleisch M; Spital G; Dietzel M; Pauleikhoff D
Graefes Arch Clin Exp Ophthalmol; 2011 May; 249(5):639-44. PubMed ID: 20890777
[TBL] [Abstract][Full Text] [Related]
11. Long-term results of intravitreal ranibizumab for the treatment of retinal angiomatous proliferation and utility of an advanced RPE analysis performed using spectral-domain optical coherence tomography.
Inoue M; Arakawa A; Yamane S; Kadonosono K
Br J Ophthalmol; 2014 Jul; 98(7):956-60. PubMed ID: 24599418
[TBL] [Abstract][Full Text] [Related]
12. [Anti-VEGF treatment for retinal angiomatous proliferation].
Wolf A; Kook D; Kreutzer T; Gandorfer A; Haritoglou C; Kampik A; Ulbig M
Ophthalmologe; 2008 Sep; 105(9):845-51. PubMed ID: 18607601
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP).
Konstantinidis L; Mameletzi E; Mantel I; Pournaras JA; Zografos L; Ambresin A
Graefes Arch Clin Exp Ophthalmol; 2009 Sep; 247(9):1165-71. PubMed ID: 19404661
[TBL] [Abstract][Full Text] [Related]
14. Subfoveal choroidal thickness changes after intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation.
Maruko I; Iida T; Oyamada H; Sugano Y; Saito M; Sekiryu T
Retina; 2015 Apr; 35(4):648-54. PubMed ID: 25627088
[TBL] [Abstract][Full Text] [Related]
15. Two-year results of combined intravitreal anti-VEGF agents and photodynamic therapy for retinal angiomatous proliferation.
Saito M; Iida T; Kano M
Jpn J Ophthalmol; 2013 Mar; 57(2):211-20. PubMed ID: 23208024
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment of photodynamic therapy with verteporfin and intravitreal ranibizumab in patients with retinal angiomatous proliferation.
Seidel G; Werner C; Weger M; Steinbrugger I; Haas A
Acta Ophthalmol; 2013 Sep; 91(6):e482-5. PubMed ID: 23786546
[TBL] [Abstract][Full Text] [Related]
17. Two-year results of combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation.
Saito M; Iida T; Kano M; Itagaki K
Jpn J Ophthalmol; 2016 Jan; 60(1):42-50. PubMed ID: 26498642
[TBL] [Abstract][Full Text] [Related]
18. One-year results of bevacizumab intravitreal and posterior sub-Tenon injection of triamcinolone acetonide with reduced laser fluence photodynamic therapy for retinal angiomatous proliferation.
Shirakata Y; Shiragami C; Yamashita A; Nitta E; Fujiwara A; Shiraga F
Jpn J Ophthalmol; 2012 Nov; 56(6):599-607. PubMed ID: 22990616
[TBL] [Abstract][Full Text] [Related]
19. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
Brown DM; Chen E; Mariani A; Major JC;
Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
[TBL] [Abstract][Full Text] [Related]
20. Vascularized retinal pigment epithelial detachment in age-related macular degeneration: treatment and RPE tear incidence.
Introini U; Torres Gimeno A; Scotti F; Setaccioli M; Giatsidis S; Bandello F
Graefes Arch Clin Exp Ophthalmol; 2012 Sep; 250(9):1283-92. PubMed ID: 22350060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]